Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
about
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysisClinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-AnalysisMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancersVISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaImmunosuppressive strategies that are mediated by tumor cellsPD-L1 regulates the development, maintenance, and function of induced regulatory T cellsMapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells.Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5.Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.Genome-Edited T Cell Therapies.Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Novel therapeutic strategies in the treatment of triple-negative breast cancer.VISTA Regulates the Development of Protective Antitumor Immunity.Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma modelPD-1 regulates extrathymic regulatory T-cell differentiation.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerTargeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapyMolecular alterations in glioblastoma: potential targets for immunotherapy.Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvantNovel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysisRepeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a case report.Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma.B7 molecule mRNA expression in colorectal carcinomaCervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion.Immunity, cancer and aging: lessons from mouse models.Challenges and future perspectives of T cell immunotherapy in cancerProgrammed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma.Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
P2860
Q26775460-BD1EC911-1E9B-4A24-9989-264BE6BED6C4Q26778025-84AE1DA2-5C7D-470F-A50F-7C18212B011FQ26852437-E7E93957-053E-4F4A-84D1-B127B0D5EF3EQ27304386-EF5BA92B-D84D-4D75-9DAB-89E1CF03849AQ28306431-4671562F-10AA-47B6-AD41-0E61C9F6B711Q28504888-940EE7A1-B2F8-47C0-9AC3-C3219EEE5257Q29620812-A4D6C996-BE81-421C-B95C-095E1D9550ACQ29636247-85170C3F-B548-4A8A-BA92-2BF9545B5F44Q30080038-C3831F9E-29F2-47D9-B017-DEEEF76CE504Q30578330-45D44109-C190-40D9-8A92-AA77545E9A85Q30916013-350CCE31-207B-4D2C-9D5E-6F639454CD7DQ33320890-9B862D55-58F2-4A73-8672-8ED2B07C2BA3Q33442162-AE07A42D-AF73-4E7B-AFDB-2D100EDAECC3Q33574520-5EEC3A42-562F-46CF-8BB6-B0F8C3A16012Q33633839-1E9111AD-4077-457A-9D96-82DE203A9792Q33688982-2C5A1A30-E796-445C-96F9-D00C19826409Q33728267-861F77B2-FD02-40D7-AE46-42E2039FFC1DQ33729598-3B3CC3B6-BFF5-4EA7-8036-ECBFAE774406Q33750205-3EFBB4CB-6316-45EC-ABFD-7756F567DF0CQ33887682-9C0D642D-5D5C-4148-BB0C-48037C9A61E6Q33978040-885C2516-4B8B-4A19-9C88-73CA2302BE2EQ34028436-039FB89A-945A-4FA3-853C-5DDA0CD0B8AAQ34195209-4C1CAED9-CA24-4D9E-867A-1EFDFCD3BA29Q34270064-87D6388D-2842-477F-9655-50527B961CEAQ34473451-F0500989-CD86-41A4-8E3A-6B1C747CCE14Q34493921-803F34FA-4B5C-43BA-BDDD-55504333C01CQ34552989-AEE2BB41-28E2-47E9-9682-7AB22E7A2847Q34594769-8FA34706-6F4B-48B1-8A4F-507F9B2EA47EQ34870511-EE164E57-264B-4062-B808-FB84F2E7C99BQ35125382-91099742-592D-45DB-B6DE-8CB64BB35310Q35221521-ADF2F2FC-AB62-4648-B1DC-7D097EC60AB1Q35290679-B4FFD37A-B4BE-4596-87F1-89D15DBB438DQ35676954-2910E2EF-ED9D-4C3D-8E84-2EDA5F4BBF1CQ35760717-A6C36024-3CEC-4CB1-840B-82160CAEA77EQ35784085-CEBFF51D-B6E9-4FF5-A49D-5B6F5C4958A4Q35798899-64444A18-4D95-483B-A6C6-34DC3F27EBBDQ35806782-9CDF4D13-77DA-4115-93A6-D80759B84B11Q35843507-577D96E2-AF01-467A-A11C-4745D9FCEFC0Q35871051-62FD8FCC-EDFE-4A96-ABC7-654D17087E08Q36193004-3D498CF3-F723-4B50-98D8-0927204DC1CD
P2860
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Interaction of PD-L1 on tumor ...... tions for tumor immunotherapy.
@ast
Interaction of PD-L1 on tumor ...... tions for tumor immunotherapy.
@en
type
label
Interaction of PD-L1 on tumor ...... tions for tumor immunotherapy.
@ast
Interaction of PD-L1 on tumor ...... tions for tumor immunotherapy.
@en
prefLabel
Interaction of PD-L1 on tumor ...... tions for tumor immunotherapy.
@ast
Interaction of PD-L1 on tumor ...... tions for tumor immunotherapy.
@en
P2093
P1476
Interaction of PD-L1 on tumor ...... tions for tumor immunotherapy.
@en
P2093
Andreas Mackensen
Christian Blank
Thomas F Gajewski
P2888
P304
P356
10.1007/S00262-004-0593-X
P577
2004-12-15T00:00:00Z